<DOC>
	<DOCNO>NCT00981240</DOCNO>
	<brief_summary>Primary objective : - To determine maximum tolerate dose ( MTD ) SAR103168 characterize dose limit toxicity ( DLTs ) propose dose regimen - To evaluate pharmacokinetic ( PK ) profile SAR103168 Secondary objective : - To characterize global safety profile SAR103168 - To evaluate preliminary anti-leukemia activity - To investigate potential induction effect CYP3A4 persistence effect use oral midazolam probe substrate patient enrol expanded cohort MTD - To determine metabolic pathway SAR103168 identify chemical structure metabolites - To determine potential impact SAR103168 QTc interval patient enrol MTD</brief_summary>
	<brief_title>Dose Escalation , Safety Pharmacokinetic Study SAR103168 Patients Refractory/ Relapsed Acute Leukemias High-risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>Patients receive study drug unacceptable toxicity , clinically significant disease progression , withdrawal consent investigator 's decision , maximum 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients refractory/relapsed acute leukemias highrisk myelodysplastic syndrome curative option available include follow : Patients de novo secondary acute myelogenous leukemia ( AML ) ( except acute promyelocytic leukemia ) , meet one follow condition : Refractory relapse AML ; In case first relapse CR duration le 12 month . If relapse fail least one prior salvage attempt , CR duration may 12 month . Into expand cohort MTD , previously untreated AML patient age 60 poor risk cytogenetics eligible accept induction chemotherapy may also include . Patients refractory/relapsed acute lymphoblastic leukemia ( ALL ) Patients highrisk myelodysplastic syndrome ( MDS ) define International Prognostic Scoring System Patients chronic myeloid leukemia blast phase ( CMLBP ) performance status &gt; 2 Active uncontrolled central nervous system leukemia Cytotoxic therapy within 2 week prior first dose SAR103168 . For non cytotoxic agents/investigational drug washout period least 2 week least 5 halflives whichever longer . Hydroxyurea must stop least 24 hour prior first dose SAR103168 Lack recovery toxicity prior therapy grade &lt; 1 White blood cell &gt; 30 x 10^9/L prior first dose SAR103168 Prior allogeneic stem cell transplantation donor lymphocytes infusion within 3 month precede first dose SAR103168 Any follow within 6 month prior first dose SAR103168 : Myocardial infarction , congestive heart failure , document angina pectoris , arrhythmia require medication ( particular atrial fibrillation flutter ) , severe conduction disorder ( second third atrioventricular block , pacemaker ) , coronary/peripheral artery bypass graft surgery Arterial venous thromboembolism , deep venous thrombosis Left ventricular ejection fraction &lt; 50 % echocardiography multiple gated acquisition scan Cardiac ischemia 12lead ECG Baseline QTcinterval &gt; 500 msec Hypertension uncontrolled appropriate therapy Active infection ( viral , bacterial fungal ) uncontrolled appropriate therapy Major surgery within 6 week prior first dose SAR103168 Poor organ function define one following : Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) unless relate leukemia ( i.e . hemolysis ) Gilbert 's syndrome Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &gt; 2.5 x ULN Serum creatinine &gt; 1.5 x ULN calculate creatinine clearance &lt; 50 mL/min Patients treatment potent inhibitor CYP3A4 unless treatment may stop least 3 day prior first dose SAR103168 Patients treatment CYP3A4 CYP2C9 inducer , unless treatment may stop least 3 day prior first dose SAR103168 Pregnant breastfeed woman refusal use adequate contraceptive method , applicable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>